[Skip to Content]
[Skip to Content Landing]
Article
August 15, 1966

Treatment of Refractory Reticulum Cell Sarcoma With Low Doses of Vincristine Sulfate

Author Affiliations

From the Cancer Service, US Public Health Service Hospital, Department of Medicine, Harvard Medical School, the Blood Research Laboratory, New England Medical Center Hospitals, and the Department of Medicine, Tufts University School of Medicine, Boston. Dr. Yount was formerly a senior fellow of the Cancer Service, US Public Health Service Hospital, Boston. He is now at Rockefeller University, New York. Dr. Finkel is a fellow in Hematology at the New England Medical Center Hospitals and a teaching fellow of the Department of Medicine, Tufts University School of Medicine, Boston. He is now at the US Public Health Service Hospital, Boston.

JAMA. 1966;197(7):535-538. doi:10.1001/jama.1966.03110070059016
Abstract

Small doses of vincristine sulfate produced dramatic improvement in patients with far-advanced reticulum cell sarcoma which previously had been resistant to other forms of therapy. The maximal initial dose was 25μg/kg body weight weekly; maintenance levels have been as low as 5μg/kg biweekly. This dosage schedule permitted prolonged courses of therapy and minimized toxicity, thus providing sustained antitumor effect. In one patient with disseminated reticulum cell sarcoma refractory to alkylating agents and irradiation, a 17-month course of therapy was tolerated without toxicity. Death, due to unrelated causes, occurred 29 months after initiation of vincristine; no tumor was found at autopsy. It is suggested that vincristine, given in small doses for weeks or months, is a systemic agent worthy of consideration for the primary therapy of generalized reticulum cell sarcoma.

×